Gregory W. Roloff, Ibrahim Aldoss, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K. Gupta, Timothy E. O'Connor, Nikeshan Jeyakumar, Ibrahim N. Muhsen, Yannis Valtis, Naveed Ahmed, Amy Zhang, Katharine Miller, Kaitlyn C. Dykes, Mohamed Ahmed, Evan C. Chen, Santiago Mercadal, Marc Schwartz, Sean I. Tracy, Bhagirathbhai Dholaria, Akash Mukherjee, Minoo Battiwalla, Aaron C. Logan, Abdullah Ladha, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Matthew P. Connor, LaQuisa C. Hill, Stephanie B. Tsai, Joshua P. Sasine, Melhem M. Solh, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Jessica T. Leonard, Noelle V. Frey, Jae H. Park, Marlise R. Luskin, Veronika Bachanova, Ahmed Galal, Vinod Pullarkat, Wendy Stock, Ryan D. Cassaday, Bijal D. Shah, Rawan Faramand, Lori Muffly, Caspian Oliai, George Yaghmour, Katherine Sutherland, Hector Zambrano, Danielle Bradshaw, Michal Kubiak, Navneet Majhail, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Anjali S. Advani, Maryann Stefan, Kristen M. O'Dwyer, Catherine J. Lee, Betsy Blunk, Michael R. Bishop. "Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.24.00321